This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
HAYES, Inc. Impella CP (Abiomed) for use in adult patients with cardiogenic shock. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017
Cardiogenic shock (CS) is an acute life-threatening condition resulting from inadequate blood circulation due to the inability of the heart (most often the left ventricle) to adequately meet systemic tissue demands for oxygen and nutrients.
The Impella CP is an intravascular nonpulsatile axial blood pump designed to support the circulatory system during CS, low output syndrome, or other conditions. Typically, it is inserted percutaneously through the
femoral artery and threaded into the left ventricle where it pumps blood from the left ventricle into the aorta. The Impella CP has a 14 Fr diameter and pumps at a rate of 3 to 4 liters per minute (L/min).
The Impella CP is intended for short-term use (< 4 days) for the treatment of ongoing CS that occurs within 48 hours following AMI or open heart surgery as a result of isolated left ventricular failure that is unresponsive to optimal medical management and conventional treatment measures of pressors, inotropic agents, and intra-aortic balloon pump.
Subject indexing assigned by CRD
Heart-Assist Devices; Humans; Intra-Aortic Balloon Pumping; Shock, Cardiogenic
Country of organisation
An English language summary is available.
Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: firstname.lastname@example.org
Date abstract record published